other material
confidence high
sentiment positive
materiality 0.75
Elicio reports ELI-002 Phase 1 data: median RFS not reached vs 3.9 months, HR=0.14
Elicio Therapeutics, Inc.
- Median RFS not reached for high T cell responders vs 3.9 months for low (HR=0.14; p=0.013).
- 86% reduction in risk of progression or death in patients with large T cell responses.
- Tumor biomarker reduction/clearance -86.9% vs -1.0% in above vs below median T cell responders (p<0.0017).
- Plan to initiate randomized Phase 2 study of ELI-002 7P in adjuvant PDAC patients early 2024.
- No ≥Grade 3 treatment-related AEs; safety profile supports further development.